Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 54
Summary
- Conditions
- Colorectal Adenocarcinoma
- Metastatic Colorectal Cancer
- Metastatic Pancreatic Cancer
- Pancreatic Adenocarcinoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03376659
- Collaborators
- Mayo Clinic
- Indiana University
- Emory University
- National Cancer Institute (NCI)
- George Mason University
- Thomas Jefferson University
- MedImmune LLC
- Bavarian Nordic
- Investigators
- Study Chair: Michael Pishvaian, MD PhD M.D. Anderson Cancer Center
Get Well Soon